Emibetuzumab (Anti-HGFR / c-Met) | c-Met | Read Reviews & Product Use Citations

Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.

Purity & Quality Control

≥99

Choose Selective c-Met Inhibitors

Biological Activity

Description	Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD.

References
[1] Liu L, et al. Clin Cancer Res. 2014 Dec 1;20(23):6059-70.

References

[1] Liu L, et al. Clin Cancer Res. 2014 Dec 1;20(23):6059-70.

Product Details

CAS No.	1365287-97-3
Molecular Weight	144.56
Isotype	Human IgG4SP
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field